Literature DB >> 23748486

Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.

Yukinori Takenaka1, Hironori Cho, Masashi Yamamoto, Susumu Nakahara, Yoshifumi Yamamoto, Hidenori Inohara.   

Abstract

PURPOSE: Febrile neutropenia (FN) is an oncologic emergency, and its management is critical during chemotherapy. However, little is known about FN in patients with head and neck cancer. The purpose of this study was to investigate the incidence and predictors of FN in patients with head and neck cancer.
METHODS: We performed a retrospective study in a university hospital in Japan between January 2008 and December 2012. Head and neck cancer patients treated with a platinum-based regimen were included in the analysis.
RESULTS: FN occurred in 47 out of 138 cycles, and the incidence of FN was highest during the first cycle. Severe sepsis or more serious events were observed in 46 % of FN episodes. Patients treated with TPF (docetaxel, cisplatin, and fluorouracil) were more susceptible to FN than those treated with DC (docetaxel, cisplatin). The patient-specific risk factors revealed using univariate analysis were tube feeding, the presence of diabetes mellitus, and gastrointestinal adverse effects. Of these, logistic regression analysis demonstrated tube feeding and diabetes mellitus as independent predictors of FN.
CONCLUSIONS: The incidence of FN in head and neck cancer patients in the community setting is higher than previously reported. Patients receiving enteral nutrition and those with diabetes are at high risk for FN.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23748486     DOI: 10.1007/s00520-013-1873-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  23 in total

1.  History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium.

Authors:  Marni Stott-Miller; Chu Chen; Shu-Chun Chuang; Yuan-Chin Amy Lee; Stefania Boccia; Hermann Brenner; Gabriela Cadoni; Luigino Dal Maso; Carlo La Vecchia; Philip Lazarus; Fabio Levi; Keitaro Matsuo; Hal Morgenstern; Heiko Müller; Joshua Muscat; Andrew F Olshan; Mark P Purdue; Diego Serraino; Thomas L Vaughan; Zuo-Feng Zhang; Paolo Boffetta; Mia Hashibe; Stephen M Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-05       Impact factor: 4.254

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

3.  Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.

Authors:  Mehran Baghi; Markus Hambek; Angelika May; Andreas Radeloff; Wolfgang Gstoettner; Rainald Knecht
Journal:  Anticancer Res       Date:  2006 Jan-Feb       Impact factor: 2.480

4.  Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.

Authors:  Michael Cullen; Neil Steven; Lucinda Billingham; Claire Gaunt; Mark Hastings; Peter Simmonds; Nicholas Stuart; Daniel Rea; Mark Bower; Indrajit Fernando; Robert Huddart; Simon Gollins; Andrew Stanley
Journal:  N Engl J Med       Date:  2005-09-08       Impact factor: 91.245

5.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

Review 6.  Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer.

Authors:  David I Rosenthal; Jan S Lewin; Avraham Eisbruch
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

Review 7.  Dysphagia in head and neck cancer patients treated with chemoradiotherapy.

Authors:  Nele Platteaux; Piet Dirix; Eddy Dejaeger; Sandra Nuyts
Journal:  Dysphagia       Date:  2009-08-27       Impact factor: 3.438

8.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

9.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Authors:  Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

Review 10.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Gary H Lyman
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

View more
  5 in total

1.  Candidemia in patients with head and neck cancer: mortality and a novel risk factor.

Authors:  Kensuke Uraguchi; Takuma Makino; Shin Kariya; Youhei Noda; Hidenori Marunaka; Akira Doi; Kenichi Kozakura; Soshi Takao; Mizuo Ando
Journal:  Support Care Cancer       Date:  2022-04-06       Impact factor: 3.603

Review 2.  The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: A systematic review with meta-analysis.

Authors:  Ebtihag O Alenzi; George A Kelley
Journal:  J Diabetes Complications       Date:  2016-09-21       Impact factor: 2.852

Review 3.  Glycemic Excursion, Adverse Drug Reactions, and Self-Management in Diabetes Patients Undergoing Chemotherapy: A Literature Review.

Authors:  Naoko Terao; Kumi Suzuki
Journal:  Asia Pac J Oncol Nurs       Date:  2021-10-04

4.  Clinical and Epidemiological Characteristics of Bloodstream Infections in Head and Neck Cancer Patients: A Decadal Observational Study.

Authors:  Shiori Kitaya; Risako Kakuta; Hajime Kanamori; Akira Ohkoshi; Ryo Ishii; Kazuhiro Nomura; Koichi Tokuda; Yukio Katori
Journal:  J Clin Med       Date:  2022-08-17       Impact factor: 4.964

5.  Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma.

Authors:  Marie Shimanuki; Yorihisa Imanishi; Yoichiro Sato; Nana Nakahara; Daisuke Totsuka; Emiri Sato; Sena Iguchi; Yasuo Sato; Keiko Soma; Yasutomo Araki; Seiji Shigetomi; Satoko Yoshida; Kosuke Uno; Yusuke Ogawa; Takehiro Tominaga; Yuichi Ikari; Junko Nagayama; Ayako Endo; Koshiro Miura; Takuya Tomioka; Hiroyuki Ozawa; Kaoru Ogawa
Journal:  Oncotarget       Date:  2018-04-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.